HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Injectable polypeptide-engineered hydrogel depot for amplifying the anti-tumor immune effect induced by chemo-photothermal therapy.

Abstract
The immunosuppressive tumor microenvironment has caused great obstacles to tumor immunotherapy, especially where less tumor-associated antigens are released from tumor sites. Herein, a Ag2S QD/DOX/Bestatin@PC10ARGD genetically engineered polypeptide hydrogel PC10ARGD as a sustained-release material was developed for mammary carcinoma treatment. A near-infrared silver sulfide (Ag2S) QD as a photosensitizer was encapsulated into the hydrophobic cavity formed by the self-assembly of the polypeptide nanogel (PC10ARGD) for photothermal therapy. The water-soluble drug DOX and Bestatin were integrated into the PC10ARGD hydrogel. The photothermal effect could trigger the sustained release of the DOX, which could be applied to initiate in situ vaccination. Bestatin as an immune-adjuvant drug could amplify the body's immune function. The results of in vivo therapy tests exhibited that the Ag2S QD/DOX/Bestatin@PC10ARGD hydrogel with laser irradiation could activate anti-tumor immune effects that inhibit the growth of primary tumors and distal lung metastatic nodules. Meanwhile, a safer lower-temperature with multiple laser irradiation treatment strategy exhibited more effective tumor-killing performance (84.4% tumor inhibition rate) and promoted the penetration of immune cells into the tumor tissue. The CD8+ and CD4+ cytotoxic T cells ratio was increased by 5.3 and 10 times, respectively, thus exhibiting a good prognostic signal. The multifunctional polypeptide hydrogel as a green manufacturing and engineering material is promising to serve as a cancer vaccine for anticancer applications.
AuthorsXiao-Lin Hou, Xiang Dai, Jie Yang, Bin Zhang, Dong-Hui Zhao, Chao-Qing Li, Zhong-Yuan Yin, Yuan-di Zhao, Bo Liu
JournalJournal of materials chemistry. B (J Mater Chem B) Vol. 8 Issue 37 Pg. 8623-8633 (09 30 2020) ISSN: 2050-7518 [Electronic] England
PMID32821893 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Video-Audio Media)
Chemical References
  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Drug Carriers
  • Hydrogels
  • Peptides
  • Photosensitizing Agents
  • Silver Compounds
  • Doxorubicin
  • silver sulfide
  • Leucine
  • ubenimex
Topics
  • Adjuvants, Immunologic (administration & dosage, chemistry, therapeutic use)
  • Animals
  • Antineoplastic Agents (administration & dosage, chemistry, therapeutic use)
  • Breast Neoplasms (drug therapy)
  • CD4-Positive T-Lymphocytes (metabolism)
  • CD8-Positive T-Lymphocytes (metabolism)
  • Cell Line, Tumor
  • Doxorubicin (administration & dosage, chemistry, therapeutic use)
  • Drug Carriers (administration & dosage, chemistry, toxicity)
  • Drug Liberation
  • Drug Therapy
  • Female
  • Hydrogels (administration & dosage, chemistry, toxicity)
  • Infrared Rays
  • Injections, Subcutaneous
  • Leucine (administration & dosage, analogs & derivatives, chemistry, therapeutic use)
  • Mice, Inbred BALB C
  • Peptides (administration & dosage, chemistry, toxicity)
  • Photosensitizing Agents (administration & dosage, radiation effects, therapeutic use)
  • Photothermal Therapy
  • Quantum Dots (administration & dosage, radiation effects, therapeutic use)
  • Silver Compounds (administration & dosage, radiation effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: